On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
Zacks Investment Research on MSN
Will AbbVie's neuroscience franchise aid top-line growth in Q1?
AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the ...
As of Monday, April 13, Alto Neuroscience, Inc.’s ANRO share price has surged by 6.32%, which has investors questioning if ...
An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...
A new study found that depression may increase the risk of menstrual pain through factors like sleep disturbances. The findings suggest that treating sleep and mental health issues may help relieve ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...
How does the amygdala influence drinking? New research shows sex-specific neural pathways: amygdala reactivity leads to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results